Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Ann Oncol ; 31(8): 1065-1074, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32442581

RESUMEN

BACKGROUND: Cancer diagnostics and surgery have been disrupted by the response of health care services to the coronavirus disease 2019 (COVID-19) pandemic. Progression of cancers during delay will impact on patients' long-term survival. PATIENTS AND METHODS: We generated per-day hazard ratios of cancer progression from observational studies and applied these to age-specific, stage-specific cancer survival for England 2013-2017. We modelled per-patient delay of 3 and 6 months and periods of disruption of 1 and 2 years. Using health care resource costing, we contextualise attributable lives saved and life-years gained (LYGs) from cancer surgery to equivalent volumes of COVID-19 hospitalisations. RESULTS: Per year, 94 912 resections for major cancers result in 80 406 long-term survivors and 1 717 051 LYGs. Per-patient delay of 3/6 months would cause attributable death of 4755/10 760 of these individuals with loss of 92 214/208 275 life-years, respectively. For cancer surgery, average LYGs per patient are 18.1 under standard conditions and 17.1/15.9 with a delay of 3/6 months (an average loss of 0.97/2.19 LYGs per patient), respectively. Taking into account health care resource units (HCRUs), surgery results on average per patient in 2.25 resource-adjusted life-years gained (RALYGs) under standard conditions and 2.12/1.97 RALYGs following delay of 3/6 months. For 94 912 hospital COVID-19 admissions, there are 482 022 LYGs requiring 1 052 949 HCRUs. Hospitalisation of community-acquired COVID-19 patients yields on average per patient 5.08 LYG and 0.46 RALYGs. CONCLUSIONS: Modest delays in surgery for cancer incur significant impact on survival. Delay of 3/6 months in surgery for incident cancers would mitigate 19%/43% of LYGs, respectively, by hospitalisation of an equivalent volume of admissions for community-acquired COVID-19. This rises to 26%/59%, respectively, when considering RALYGs. To avoid a downstream public health crisis of avoidable cancer deaths, cancer diagnostic and surgical pathways must be maintained at normal throughput, with rapid attention to any backlog already accrued.


Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/epidemiología , Neoplasias/epidemiología , Neoplasias/cirugía , Pandemias/prevención & control , Neumonía Viral/epidemiología , Tiempo de Tratamiento/tendencias , Adulto , Anciano , Anciano de 80 o más Años , COVID-19 , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/terapia , Femenino , Hospitalización/tendencias , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/diagnóstico , Neumonía Viral/diagnóstico , Neumonía Viral/terapia , SARS-CoV-2 , Resultado del Tratamiento
2.
Colorectal Dis ; 15(4): 442-7, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22966859

RESUMEN

AIM: The aim of the study was to compare outcomes for emergency management of diverticulitis before and after the creation of a regional subspecialist colorectal unit. METHOD: We retrieved data on all emergency admissions for diverticulitis from the regional surgical audit database and compared results before (January 1998 to August 2002) and after (August 2002 to December 2008) establishment of the subspecialist colorectal surgery unit in August 2002. Additional data were retrieved from electronic patient records. The primary outcome measures were mortality and rate of primary anastomosis following resection. RESULTS: There were 879 patients before and 1280 patients after subspecialization. Nonoperative management was undertaken in approximately 80% of cases. Total mortality fell from 3.3 to 1.5% (P = 0.008), attributable to reduced operative mortality (9.6 to 4.2%; P = 0.019). The primary anastomosis rate for all left colon resections increased from 50.3 to 77.9%; P < 0.0001. Stoma formation of any type fell from 46.6 to 27.7%; P < 0001). CONCLUSION: Emergency management of diverticulitis by subspecialist colorectal surgeons is associated with low overall and operative mortality whilst safely achieving high rates of primary anastomosis.


Asunto(s)
Cirugía Colorrectal , Diverticulitis del Colon/cirugía , Íleon/cirugía , Recto/cirugía , Especialización , Anciano , Anastomosis Quirúrgica/mortalidad , Anastomosis Quirúrgica/estadística & datos numéricos , Colectomía/mortalidad , Colectomía/estadística & datos numéricos , Diverticulitis del Colon/mortalidad , Diverticulitis del Colon/terapia , Urgencias Médicas , Femenino , Humanos , Ileostomía/mortalidad , Ileostomía/estadística & datos numéricos , Masculino , Escocia/epidemiología
4.
J Nutr ; 129(4): 872-7, 1999 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10203563

RESUMEN

Parasite-specific plasma immunoglobulins have been used to indicate the presence of Giardia intestinalis infection in 60 infants living in a rural area of The Gambia. Infants were studied longitudinally between 2 and 8 mo of age. The median age for first exposure to G. intestinalis was between 3 and 4 mo, and by 8 mo all but 3 infants (95%) showed a positive titer on at least one occasion. Raised Giardia-specific IgM titers were associated with reduced weight gain in the 2 wk preceding a positive titer, but catch-up growth occurred in the following 2 wk. IgM antibody titers were also positively associated with intestinal permeability (lactulose/mannitol ratio), urinary lactose excretion, plasma concentrations of alpha1-antichymotrypsin and total IgM, IgA and IgG immunoglobulins. However, infant growth over the whole 6-mo period (i.e., between 2 and 8 mo of age) was not related to mean Giardia-specific antibody titers, nor the time of first exposure to the parasite. The data suggest that giardiasis in these very young breast-fed children occurs as a mild, acute disease, and its presence could not explain the marked, long-term growth faltering observed in many of the subjects.


Asunto(s)
Anticuerpos Antiprotozoarios/sangre , Giardia lamblia , Giardiasis/complicaciones , Trastornos del Crecimiento/etiología , Análisis de Varianza , Animales , Diarrea/epidemiología , Diarrea/parasitología , Gambia/epidemiología , Giardiasis/epidemiología , Giardiasis/inmunología , Humanos , Inmunoglobulina A/sangre , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Lactante , Estudios Longitudinales , Prevalencia , Población Rural , Estaciones del Año , alfa 1-Antiquimotripsina/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA